Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
XENON XE 133 vs XENON XE 127
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Xenon Xe 133 is a radioactive gas that emits gamma radiation. It is used as a tracer in pulmonary ventilation studies and regional cerebral blood flow measurements. The mechanism relies on its physical properties as an inert radioactive gas that diffuses across alveolar-capillary membranes and is distributed according to regional ventilation and perfusion.
Xenon Xe 127 is a radioactive isotope that emits gamma radiation and is used as a diagnostic imaging agent. Its mechanism is based on the physical properties of radioactive decay, allowing for scintigraphic imaging of pulmonary ventilation and cerebral blood flow.
Pulmonary ventilation imaging (FDA approved),Regional cerebral blood flow evaluation (FDA approved)
Pulmonary ventilation imaging to evaluate regional lung function,Cerebral blood flow imaging for assessment of perfusion
5-10 m Ci (185-370 MBq) inhaled or intravenously as a single dose for pulmonary ventilation/perfusion imaging.
5-10 m Ci (185-370 MBq) inhaled as a single dose for pulmonary ventilation studies.
Terminal elimination half-life: 1.5–2 minutes (fast washout from well-perfused tissues); total-body elimination half-life approximately 5–7 minutes due to slow release from adipose tissue. Clinical context: rapid clearance allows repeated imaging within short intervals.
Terminal elimination half-life is approximately 5 minutes for the washout phase from well-perfused tissues. In poorly perfused fat, a slower phase with half-life of ~30 minutes may occur. Clinically, the gas is rapidly cleared from the body upon cessation of administration.
Xenon Xe 133 is inert and not metabolized; it is eliminated unchanged via exhalation.
Not metabolized; eliminated via exhalation unchanged.
Primarily eliminated via exhalation through the lungs (>95% unchanged); minimal renal excretion (<5% as dissolved gas).
Primarily eliminated via exhalation as unchanged gas (>95%). Minimal renal excretion of dissolved xenon (<5%). No biliary or fecal elimination due to inert nature.
Negligible (<5%); Xenon is a noble gas and does not bind appreciably to plasma proteins.
Negligible protein binding (<1%). Xenon is inert and does not bind significantly to plasma proteins.
Volume of distribution: 13–15 L/kg (large due to high lipid solubility, extensive distribution into fat and other tissues). Clinical meaning: indicates rapid and widespread tissue uptake, with adipose tissue as a slow-release reservoir.
Volume of distribution is approximately 3-5 L/kg, reflecting extensive distribution to tissues including fat, due to high lipid solubility.
Inhalation: near 100% (gas is fully absorbed from alveoli into the bloodstream; intravenous injection not used clinically).
Inhalation: Bioavailability is 100% due to direct delivery to pulmonary circulation. No other routes are clinically relevant.
No dose adjustment required; xenon is eliminated via exhalation.
No adjustment required as Xenon Xe 127 is eliminated via exhalation.
No dose adjustment required; xenon elimination is independent of hepatic function.
No adjustment required as Xenon Xe 127 is not hepatically metabolized.
0.1-0.3 m Ci/kg (3.7-11.1 MBq/kg) inhaled or intravenous, minimum 2 m Ci (74 MBq), maximum 10 m Ci (370 MBq).
0.1-0.2 m Ci/kg (3.7-7.4 MBq/kg) inhaled, maximum 10 m Ci.
Use lowest effective dose; consider reduced respiratory function but no specific dose adjustment required.
No specific adjustment; use standard adult dose with caution due to potential reduced pulmonary function.
None.
None.
Radiation exposure risk; minimize dose and duration.,Use with caution in patients with impaired pulmonary function.,Pregnancy category C; use only if benefit outweighs risk.,Lactation: discontinue nursing or drug.,Ensure adequate ventilation to prevent accumulation of exhaled gas.
Radiation exposure risk; use only when necessary in pregnant women and children.,Ensure proper handling and disposal to minimize exposure to personnel and environment.
None specifically documented; contraindicated in patients with known hypersensitivity to xenon or components.
Hypersensitivity to xenon or any component of the product.,Known or suspected pregnancy unless benefit outweighs risk.
No food or drug interactions; no dietary restrictions required with Xenon Xe 133.
No specific food interactions. However, patients should avoid heavy meals immediately before the study to prevent aspiration or discomfort during inhalation. No dietary restrictions otherwise.
Xenon Xe 133 is a radioactive gas used for diagnostic imaging. Limited data in pregnancy; radiation exposure carries risk of teratogenicity, especially during organogenesis (first trimester). Use only if benefit outweighs risk. Second and third trimester risk is lower but consider fetal radiation exposure.
Xenon Xe 127 is a radioactive gas. Exposure during pregnancy poses a risk of fetal radiation exposure. First trimester: highest risk for teratogenicity (e.g., CNS malformations, growth restriction). Second trimester: risk of growth restriction and neurodevelopmental effects. Third trimester: risk of childhood cancer and growth restriction. Consider alternative imaging modalities.
No data on excretion in breast milk. Discontinue breastfeeding temporarily after administration. Advise pump and discard milk for at least 24 hours post-exposure. M/P ratio unknown.
No data on M/P ratio. Xenon Xe 127 is rapidly excreted via lungs; minimal secretion into breast milk is expected, but due to radioactivity, breastfeeding should be interrupted for at least 48 hours post-administration.
No dose adjustment is recommended based on pharmacokinetic changes; however, consider minimizing fetal radiation exposure by using lowest effective dose and shortest scan time.
No dosing adjustments established for pregnancy. Use lowest effective activity and minimize exposure time. Consider non-radioactive alternative due to risks.
Xenon Xe 133 is a radiopharmaceutical gas used for pulmonary ventilation scintigraphy. Its short half-life (5.24 days) allows for serial studies with minimal radiation exposure. Ensure patient has not recently undergone other nuclear medicine studies to avoid interference. Administer via closed breathing system to prevent environmental contamination. Image acquisition typically during equilibrium and washout phases. Adverse effects are rare but include dizziness, headache, or metallic taste.
Xenon Xe 127 is a radioactive gas used in pulmonary ventilation studies. It is administered via inhalation. Key pearls: (1) Ensure patient does not smoke or use nicotine products for at least 6 hours prior to study to reduce background activity. (2) Scintigraphy must be performed promptly after inhalation due to short half-life (36.4 days). (3) Contamination risk is low but proper ventilation and waste disposal are critical. (4) Contraindicated in severe COPD or respiratory distress due to inability to hold breath.
This is a radioactive gas used to image lung function.,You will inhale the gas through a mouthpiece or mask while lying under a camera.,The amount of radiation is very low and considered safe.,No special precautions are needed after the test; you can resume normal activities.,Drink plenty of fluids after the test unless instructed otherwise.
This is a radioactive gas used to image lung ventilation.,You will inhale the gas through a mouthpiece or mask; no pain is involved.,The radiation exposure is low and similar to a chest X-ray.,Avoid smoking or using nicotine for 6 hours before the test.,Inform your doctor if you are pregnant or breastfeeding.,You may be asked to hold your breath for 10-20 seconds.,After the test, you can resume normal activities immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about XENON XE 133 vs XENON XE 127, answered by our medical review team.
XENON XE 133 is a Radiopharmaceutical Diagnostic Agent that works by Xenon Xe 133 is a radioactive gas that emits gamma radiation. It is used as a tracer in pulmonary ventilation studies and regional cerebral blood flow measurements. The mechanism relies on its physical properties as an inert radioactive gas that diffuses across alveolar-capillary membranes and is distributed according to regional ventilation and perfusion.. XENON XE 127 is a Radiopharmaceutical Diagnostic Agent that works by Xenon Xe 127 is a radioactive isotope that emits gamma radiation and is used as a diagnostic imaging agent. Its mechanism is based on the physical properties of radioactive decay, allowing for scintigraphic imaging of pulmonary ventilation and cerebral blood flow.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between XENON XE 133 and XENON XE 127 depend on the specific clinical indication. These are both Radiopharmaceutical Diagnostic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of XENON XE 133 is: 5-10 m Ci (185-370 MBq) inhaled or intravenously as a single dose for pulmonary ventilation/perfusion imaging.. The standard adult dose of XENON XE 127 is: 5-10 m Ci (185-370 MBq) inhaled as a single dose for pulmonary ventilation studies.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between XENON XE 133 and XENON XE 127 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. XENON XE 133 is classified as Category C. Xenon Xe 133 is a radioactive gas used for diagnostic imaging. Limited data in pregnancy; radiation exposure carries risk of teratogenicity, especially during organogenesis (first . XENON XE 127 is classified as Category C. Xenon Xe 127 is a radioactive gas. Exposure during pregnancy poses a risk of fetal radiation exposure. First trimester: highest risk for teratogenicity (e.g., CNS malformations, gr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.